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Background and Aims: There is controversy about the length of low-residue 
diet (LRD) for colonoscopy preparation. The aim of the study was to compare 
one-day vs. three-day LRD associated to standard laxative treatment for 
achieving an adequate colonoscopy preparation in average risk patients 
undergoing screening colonoscopy. 
Methods: A non-inferiority, randomised, controlled, parallel-group clinical trial 
was performed in the setting of average risk colorectal cancer screening program. 
Participants in the were randomised to receive 1-day vs. 3-day LRD in addition 
to standard polyethilenglicol treatment. Adequacy of preparation was evaluated 
by using the Boston Bowel Preparation Scale (BBPS).  Primary outcome was 
achieving a BBPS ≥2 in all colon segments. Analysis was performed for a non-
inferiority margin of 5%, a 95% statistical power and one-sided 0.05 significance 
level.
Results: A total of 855 patients were randomised. Adequate bowel preparation 
was similar between groups: 97.9% of patients in the 1-day LRD group vs 96.9% 
in the 3-day LRD group achieved the primary outcome (p-value for non-inferiority 
<0.001. The percentage of patients with BBPS scores ≥ 8 was superior in 1-day 
LRD group (254 vs 221 in the 3-day LRD group, p=0.032). The 1-day regimen 
was better tolerated than the 3-day diet. A 47.7% (vs, 28.7%, p<0.05) of patients 
rated the One-day LRD as very easy to follow. 
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Conclusion: One-day LRD is non-inferior to three-day LRD for achieving an 
adequate colon cleansing before colonoscopy. These results support the use of 
one-day LRD as the standard preparation for average risk screening 
colonoscopy. Clinicaltrials.gov (NCT03763266).
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INTRODUCTION AND BACKGROUND 
Colonoscopy is the most accurate method for the evaluation of the colorectal 
mucosa. It is the method of choice to diagnose colorectal cancer (CRC)1,2  and 
for removing premalignant lesions. It has been estimated that in the US 15 million 
scheduled colonoscopies are performed each year 3,4.
The number of colonoscopies is currently increasing, due to  the introduction of 
early detection screening programs around the world 5–8 and  the resulting 
surveillance colonoscopies 5,6. In this context, adequate bowel cleansing is of 
paramount importance for improving the efficiency of the examination 8,9. 
Bowel preparation process is often considered burdensome and might have an 
impact in participation rates in populational screening programs and impact 
quality of life of subjects at increased isk of colorectal cancer that require periodic 
surveillance colonoscopies 10,11. Therefore, improving the safety and tolerability 
of the bowel cleansing preparation may help to promote participation in the 
screening programs 9,12. 
Some measures have been shown to improve bowel preparation. In this sense,  
consistent data support both the use of split dose regimens 13,14  and the reduction 
of the interval between bowel preparation and the start of colonoscopy 15. In a 
recent systematic review, low-volume polyethylene glycol (PEG) split-dose 
regimens were as effective as high-volume regimens. Furthermore, low-volume 
preparations showed better tolerance and adherence16. 
Regarding  diet before colonoscopy, low-residue diet (LRD) has been shown to 
be better tolerated than the traditionally endorsed clear liquid diet (CLD) 17–20.
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Diet restriction may have a clear impact in patient satisfaction, quality of life  and 
willingness to repeat the procedure 23,24. For this reason, it is important to assess 
the most useful duration of LRD for colon preparation not only in terms of quality 
of bowel cleansing, but also regarding tolerability and patient’ satisfaction 21,25,26. 
The aim of the present study was to compare the efficacy and tolerability of a 1-
day LRD versus a 3-day LRD colon cleansing by performing a non-inferiority 
randomised controlled clinical trial. 
METHODS 
Design and setting
Between December 2018 and January 2020, a randomised, controlled, parallel-
group clinical trial was performed in the Endoscopy Unit of the Hospital 
Universitari Parc Taulí (Sabadell, Barcelona, Spain), in the context of early CRC 
screening program of the Vallès Occidental county (Barcelona, Spain). 
The study protocol was approved by the Ethical Commission for Scientific 
Research of Fundació Parc Taulí (dated 25th July 2017) and procedures were in 
accordance with the ethical standards laid down in the Declaration of Helsinki, as 
revised in the year 2000. Written informed consent was obtained from all 
participants. The study was reported in accordance with the Consolidated 
Standards of Reporting Trials and registered in Clinicaltrials.gov (NCT03763266)
Subjects and procedures
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Participants in the early CRC detection program aged between 50 and 69 years, 
who agreed to undergo colonoscopy after positive results on the immunological 
fecal occult blood test, were eligible to participate in the study. Potential 
participants were excluded in case of contraindication to colonoscopy, patient 
refusal to participate or inability to understand the risks or give informed consent.  
Subjects were randomly assigned to receive the 1-day or the 3-day LRD regimen 
at a ratio of 1:1, using random block sizes of 6. Random sequence was created 
by the principal investigator using the Sealed Envelope® program. Allocation 
concealment was performed using sequentially numbered, opaque envelopes. 
Participants were instructed about bowel cleansing and the study protocol. Low-
volume PEG plus ascorbic acid in split-dose regimens (MoviPrep®, Norgine BV, 
Amsterdam, Netherlands), was prescribed. First dose was administered the 
evening of the day before at 20:00 h. The second dose was scheduled to finish 
2-4 hours before the colonoscopy. Dietary instructions were designed by an 
endocrinologist specialized in nutrition.  All the subjects received a logbook and 
were requested to register the diet taken during the 3 days before colonoscopy. 
Participants of both arms who reported being constipated recurrently received 
additional preparation with 5mg of bisacodyl every 12 hours during three days 
before the exploration.
All colonoscopies were performed by senior staff endoscopists, who were already 
routinely evaluating cleansing quality by using the Boston Bowel Preparation 
Scale (BBPS). Furthermore, all endoscopists repeated the BBPS Educational 
Program available at http://domweb.bumc.bu.edu/bowelprep/ before the first 
participant appointment 27. 
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Investigators involved in the study, including the endoscopy staff performing the 
BBPS were blinded to the study regimen received by the subjects. Only the 
researcher in charge of recruitment, group assignment and review of dietary 
logbooks was aware of the treatment arm.   
Variables collected
Experimental variables
BBPS was registered by the endoscopists immediately after the exploration. The 
primary outcome of the study was adequate bowel cleansing. Bowel cleansing 
was considered adequate when each colon segment was scored ≥ 2 points.  
Secondary outcomes were the rat  of patients achieving an excellent preparation 
(arbitrarily defined as an overall score of ≥8 points), preparation and diet 
tolerability, proportion of patients with adequate cleansing in each segment, 
adenoma and polyp detection rate and colonoscopy exploration times (from anus 
to cecum and withdrawal times) 
Before the colonoscopy, the participant answered a 5-point Likert scale survey 
(Table S1) designed to assess the diet and preparation tolerability. Adherence to 
diet, completeness of the laxative preparation and bisacodyl use when indicated 
were also recorded before entering the endoscopy room. Other variables 
registered during and after the colonoscopy where the endoscopist performing 
the study, colonoscopy findings and causes of incomplete exploration. Immediate 
or delayed -until 30 days- adverse events related to the procedure or the sedation 
were registered.
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Variables potentially influencing the preparation quality were also recorded: days 
from bowel preparation instructions until colonoscopy, time lapse between the 
end of preparation and the beginning of the colonoscopy, age, gender, height and 
weight for BMI calculation, antidepressant or opioid treatment, reduced mobility, 
and hepatic cirrhosis.
Sample size calculation
For sample size calculation we assumed from previous data in our center that 3-
day LRD protocol will achieve a 95% of adequate preparation28. We set power at 
95% (1-β=0.95) with an α error of 0.05 and non-inferiority margin (δ) of -5%). 
Based on this we estimated a required sample size of 824 participants, 412 per 
group. Sample size calculation was done using the Sealed Envelope® (London, 
UK program) using the power calculator for binary outcome, non-inferiority trial.
Statistical analyses
Categorical variables were described using frequencies and percentages were 
used. For quantitative variables, means (and standard deviations) or medians 
(and interquartile ranges) were used. 
Intention to treat (ITT) analysis included all randomised cases (with the exception 
of those who did not attend the colonoscopy appointment and lack information 
regarding the main outcome). Per protocol (PP) analysis included only those 
patients in whom adherence to diet was complete, intake of bowel preparation 
solution was ≥ 75% and colonoscopy was complete. Patients in whom 
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colonoscopy was incomplete because of improper cleansing were also 
considered as not achieving the primary outcome in the ITT analysis. 
Comparisons between diet groups were assessed using Student’s T-tests or the 
U-Mann Whitney for continuous variables. The chi-square test or the Fisher’s 
exact test were used for categorical variables.
A non-inferiority analysis for the primary outcome “adequate preparation” was 
performed. It was a priori planned that, if non-inferiority was demonstrated, the 
primary and secondary outcomes (excellent preparation, tolerability, adenoma 
detection rate, polyp detection rate and colonoscopy exploration times) were 
assessed for superiority. 
Univariate logistic regression models were used to estimate the effect of diet on 
the adequate bowel preparation and to identify other associated factors. 
Multivariate logistic regression models included the designated diet and 
covariates that were significant in the univariate models, providing the adjusted 
ORs. Statistical significance was considered as a p value less than 0.05. 
Statistical analysis was performed using the IBM Statistical Package for the 
Social Sciences (SPSS) program version 25.0 (SPSS, Inc. Chicago, IL) and R 
3.1.0 (R Foundation for Statistical Computing, Vienna, Austria). Reporting of the 
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A total of 1.697 consecutive subjects were assessed for eligibility, of whom 855 
were randomised into the study (429 in 1-day group and 426 in the 3-day group). 
Causes of ineligibility for the study were unwillingness to participate (n=834) and 
inability to give informed consent (n=8) (Figure 1).
ITT population included 836 patients (420 in the 1-day group and 416 in the 3-
day group), with a mean age of 54.91± 6.16 years and a mean BMI of 27.5 ± 4.4 
kg/m2 and including 56.9% of men. In both groups, 68.2% were overweighted or 
obese (BMI > 25). PP population included 826 patients (417 in the 1-day group 
and 409 in the 3-day group (see flow chart in Figure 1). Reasons of exclusion 
from the PP population included incomplete preparation intake, incomplete diet 
or incomplete colonoscopy due to reasons other than inadequate cleansing. 
Baseline and clinical characteristics were similar between groups (Table 1). 
All participants assigned to the 1-day diet completed the regimen, 4 subjects (1%) 
failed to complete the 3-day LRD. Constipation needing additional bisacodyl rates 
were similar in both groups (15.2% vs 13.7%, p = 0.604). No differences were 
observed in the baseline characteristics (Table 1). There were no significant 
differences in the days lapsed from the study enrolment until the colonoscopy 
(36.6 days vs 38.5 days; p = 0.095) as well as in the time lapsed from the end of 
the preparation until the beginning of the colonoscopy (3 hours 20 minutes (56 
minutes) vs. 3 hours 22 minutes (53 minutes), p=0.417).
Primary outcome
The percentages of patients with adequate preparation was similar between 
groups: in the ITT population, 97.9% of subjects in 1-day LRD and 96.9% in 3-
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day LRD. In the PP population, adequate preparation rates were 98.0% and 
97.7% respectively. 
Non-inferiority ITT analysis show a difference of 0.98 (unilateral 95% CI -1.07, p 
<0.001) and in the case of PP analysis 0.53 (unilateral 95% CI -1.39, p <0.001) 
(Table 2). The study requirements for demonstrating non-inferiority of 1-day LRD 
are achieved (Figure 2).
Secondary outcomes 
The proportion of patients achieving an excellent preparation
Adequacy of the cleansing per segment (BBPS score ≥ 2) in proximal, transverse 
and distal colon) was similar in both groups and all differences included in the 
non-inferiority margin. ITT data are shown in Table 3 and PP data in Table S2. 
Only the proportion of subjects with a BBPS score of 3 in the proximal colon was 
higher in the 1-day vs. the 3-day LRD arm (55% vs. 47.9%, respectively p=0.03). 
Regarding the tolerability of each regimen, 1-day LRD was significantly better 
tolerated than the 3-day diet, with 47.7% vs 28.7% rating the diet as easy to follow 
and not interfering in normal activities (Likert 1 p < 0.05), and with 77.0% vs 
60.9% having an aggregated Likert-scale scores of 1 and 2 (p < 0.01) (Table 4). 
Laxative preparation (PEG+Asc) tolerability was similar in both groups (67.8% vs. 
63.6% of patients with Likert scale scores of 1 and 2 (p=0.209) and for each score 
(Table 4). 
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No differences were observed either in the ITT nor PP analyses in the cecal 
intubation and withdrawal time. Adenoma and polyp detection rate were similar 
in both arms (72.4% vs. 72.6% p=0.94 and 77.9% vs. 75.2% p=0.37 respectively). 
Incomplete colonoscopies were due to inadequate preparation in 6 cases. Five 
of them occurred in the 3-day LRD group (p=0.09). Additional incomplete 
explorations were due to stenosis (2), loop formation (1) and adherences (1). 
The most frequent diagnosis during colonoscopy were polyps (73.4% in 1-day 
LRD group and 72.6% in 3-day LRD), followed by diverticula (7.7% vs 5.65) and 
hemorrhoids (5.0% vs 5.6%). 
Risk factors and control of confounding variables
In order to control interobserver variability in the evaluation of the BBPS we 
adjusted for the individual endoscopist in a logistic regression model. Neither in 
the univariate analysis, nor in the logistic regression model any individual variable 
was associated with an adequate cleansing (Table S3).
On the other hand, regarding excellent bowel cleansing (BBPS ≥8) multivariate 
analysis disclosed older age, higher BMI, constipation and treatment with opioids 
as risk factors for not achieving it.  After adjusting for other variables, 1-Day LRD 
was the only variable directly associated with BBPS ≥ 8 in the multivariate 
analysis and the binary logistic regression model (OR 1.5 95% CI 1.1 – 2.0 
p<0.01) (Table 5)
DISCUSSION
In our study, designed for a non-inferiority testing, we have clearly demonstrated 
that the 1-day LRD is as effective as the 3-day diet to achieve an adequate colon 
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preparation in both the non-inferiority and superiority analyses. Furthermore, 
rates of excellent colon cleansing were superior in the 1-day LRD groups. Another 
related and important finding of the present study is that 1-day LRD was 
significantly better tolerated than 3-day diet, as expected due to the reduction by 
a third in diet duration.
To our knowledge, it is the first time that the 1-day diet has been demonstrated 
to be non-inferior to the 3-day diet. In this sense, two recent clinical trials, 
comparing 1-day versus 3-day LRD, did not find statistically significant 
differences in the cleansing quality and in the polyp/adenoma rates, but these 
studies where not designed to assess non-inferiority and included small samples 
of subjects 19,30 . Better tolerability of 1-day LRD when compared to longer diet 
durations has already been reported in previous trials. This fact is also in 
consonance with a higher probability to complete 1-day LRD  and the observation 
that this regimen may provide a better preparation 19,30.  As it was observed in 
the univariate analysis 1-day LRD was associated with a higher probability of 
BBPS scores ≥ 8, which represents a high-quality preparation. Additionally, these 
results were further confirmed in the multivariate logistic regression analysis. 
One-Day LRD remained the only variable predictive of an excellent preparation 
after adjusting for confusing variables such as low tolerability to diet, treatment 
with bisacodyl and opioids and endoscopist. 
The study has some limitations. First of all, the study was performed in a sample 
of low comorbidity asymptomatic subjects. Therefore, the results cannot be 
directly extrapolated to individuals with high risk of poor cleansing as, for 
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example, symptomatic, elderly patients or to the inpatient setting. Second, we did 
not use a validated tool for assessing diet and preparation tolerability, as there 
was no free access to scales or simple questionnaires validated in Spanish or 
Catalan. Finally, we were neither able to record colonoscopies nor to undergo a 
centralized single operator evaluation or a consensus assessment of the bowel 
cleansing. However, the relevance of these limitations was limited by the large 
sample size and the effect of the randomisation and blinding. Furthermore, we 
performed a multivariate and logistic regression model that revealed no effect on 
the results and that in real life BBPS can be biased. 
Data of our study are robust enough to support the routine use of 1-day LRD diet, 
at least in the setting of routine preparation for CRC screening. This may help to 
reduce the burden of colonoscopy preparation for the patients. One-day LRD 
preparation has additional advantages: for example, reducing the number of days 
needed to perform LRD may help to manage waiting lists, as colonoscopies could 
be planned only one or two days in advance, thus allowing for example 
substitution of last-minute cancellations. 
Furthermore, the right colon has the highest rate of missed adenomas and 
flat/serrated polyps as well as interval or missed colorectal cancer, which are the 
main concern for endoscopists due to the difficulty to detect them 11,31–36. One 
reason for this fact, is the difficulty to obtain good colonic preparation in this 
particular segment 19,24,30,37,38. In this sense, the analysis of bowel preparation per 
segments in the present study revealed a higher proportion of subjects with 
adequate preparation in the right or proximal segment in the 1-day LRD arm. 
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One-day preparation may, therefore, help to reduce the rate of missing lesions 
and interval cancer. 
Finally, these results can lead to new insights in the management of colon 
preparation, in which diet could gain less importance than previously recognized. 
To date, however, these results have been obtained only in clinical trials and, 
therefore, in a selected population. Therefore, we consider that these results 
should also be confirmed in observational studies in routine clinical practice.
In conclusion, we have shown that 1-day LRD provides non-inferior results to 3-
day LRD, in terms of bowel preparation, globally and per segments. It is better 
tolerated and achieves a higher adherence. Also, 1-day LRD is associated with 
increased probability of high-quality preparation. These results support a change 
in bowel preparation restricting diet to only the day before colonoscopy in average 
risk colorectal cancer screening.
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Figure legends
Figure 1. Study flow chart
Figure 2. Difference in the percentage (%) of patients that achieved adequate 
preparations between diets with 95% CI. 
Supplementary table legends
Table S1 Diet and preparation tolerability 5 point Likert scale survey
Table S2 Per protocol segments cleansing and colonoscopy performance
Table S3 Factors related to an adequate cleansing. Results of univariate analysis.
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Age (years) 58.9 (5.4) 59.3 (5.5) ns
BMI (kg/m2) 27.5 (4.3) 27.5 (4.5) ns
≤ 25 31.8% 31.8% ns
BMI
> 25 68.2% 68.2%




Hepatic Cirrhosis 1.2% 1.0% ns
Constipation 15.2% 13.7% ns
Reduced mobility 3.3% 2.9% ns
Antidepressant treatment 11.0% 7.7% ns
Opioid treatment 2.9% 2.9% ns
Preparation and colonoscopy factors 
Preparation volume adherence  3/4 418 (96.2%) 416 (97.4%) ns
< 3/4 2 (0.5%) 0 (0%)
Addition of bisacodyl 15.2% 13.7% ns
Days until colonoscopy 36.6 (17.0) 38.5 (28.8) ns
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Intention to treat analysis
Adequate preparation or segmental BBPS ≥2. n(%)
Global BBPS 411/420 (97.9) 403/416 (96.9) 0.98 (-1.07.  ) <0.001
Proximal BBPS 414/418 (99.0) 403/410 (98.3) 0.75 (-0.80. ) <0.001
Transverse BBPS 416/419 (99.3) 408/412 (99.0) 0.25 (-1.03. ) <0.001
Distal BBPS 414/420 (98.6) 405/416 (97.4) 1.21 (-0.63. ) <0.001
Per protocol analysis
Adequate preparation or segmental BBPS ≥2. n(%)
Global BBPS 409/417 (98.1) 399/409 (97.6) 0.53 (-1.39. ) <0.001
Proximal BBPS 412/416 (99.0) 400/407 (98.3) 0.76 (-0.80. ) <0.001
Transverse BBPS 414/417 (99.3) 404/407 (99.3) 0.02 (-0.97. ) <0.001
Distal BBPS 411/417 (98.6) 401/409 (98.0) 0.52 (-1.20. ) <0.001
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Cecal intubation time (m:s) 5:00 (4:00) 5:00 (3:00) 0.292
Time lapse between end 
preparation and colonoscopy (h:m)
3:20 (0:56) 3:22 (0:53) 0.417
Withdrawal time (m:s) 13:0 10:0) 14:00 (9:00) 0.867
Total colonoscopy time (m:s) 19:00 (12:00) 19:00 (11:00) 0.322
Cleansing 
Proximal BBPS 0.029
0-1 4 (1.0%) 7 (1.7%)
2 185 (44.3%) 208 (50.7%)
3 229 (54.8%) 195 (47.6%)
Transverse BBPS 0.047
0-1 3 (0.7%) 4 (1.0%)
2 130 (31.0%) 154 (37.4%)
3 286 (68.3%) 254 (61.7%)
Distal BBPS 0.566
0-1 6 (1.4%) 11 (2.6%)
2 187 (44.5%) 184 (44.2%)
3 227 (54.0%) 221 (53.1%)
Global BBPS ≥ 8 254 (60.5%) 221 (53.1%) 0.032
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Adenoma detection 304 (72.4%) 302 (72.6%) 0.944
Polyp detection 327 (77.9%) 313 (75.2%) 0.372








Agregate diet tolerability <0.001
Likert 1-2 318 (77.0%) 248 (60.9%)
Likert 3-5 95 (23.0%) 159 (39.1%)
Agregate preparation tolerability ns
Likert 1-2 280 (67.8%) 259 (63.6%)
Likert 3-5 133 (32.2%) 148 (36.4%)
Complete diet adherence 420 (100%) 412 (99%) ns
Complete colonoscopy 418 (99.5%) 408 (98.1%) ns
Cause of uncomplete colonoscopy ns
Inadequate cleansing 1 (0.2%) 5 (1.2%)
Estenosis 1 (0.2%) 1 (0.2%)
Loop formation 0 (0%) 1 (0.2%)
Adherences 0 (0%) 1 (0.2%)
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Normal 34 (8.2%) 41 (10.0%)
Colorectal cancer 12 (2.9%) 18 (4.4%)
Polyps 306 (73.4%) 299 (72.6%)
Inflammatory colitis 3 (0.7%) 4 (1.0%)
Angiodysplasia 8 (1.9%) 1 (0.2%)
Other tumors 0 (0%) 1 (0.2%)
Diverticulae 32 (7.7%) 23 (5.6%)
Hemorroids 21 (5.0%) 23 (5.6%)
Other 1 (0.2%) 2 (1.5%)
Side effects
Adverse events 1 (0.2%) 5 (1.2%) ns
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Age (years) 0.003* 0.96 (0.94-0.98) 0.049* 0.97 (0.94-0.99)
BMI (kg/m2) 0.026* 0.96 (0.93-1.0) 0.013* 0.96 (0.92-0.99)
Sex (Male) 0.140 0.81 (0.61-1.1)
Reduced mobility 0.002 0.27 (0.11-0.65)
Antidepressant 0.202 0.74 (0.46-1.2)
Opioids 0.001* 0.24 (0.1-0.62) 0.018* 0.29 (0.11-0.81)
1-Day LRD 0.032* 1.3 (1.0-1.8) 0.008* 1.5 (1.1-2.0)
Diet compliance 0.034* 2.3 (2.1-2.5)
Low diet tolerance 0.996 1.0 (0.7-1.4)
Constipation 0.019* 0.63 (0.43-0.93) 0.021* 0.60 (0.39-0.93)
Low preparation tolerance 0.092 0.80 (0.58-1.0)
Days until colonoscopy 0.236 0.99 (0.99-1.0)
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Figure 1 Study flow chart 
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Figure 2 Difference in the percentage (%) of patients that achieved adequate preparations between diets 
with 95% CI. 
249x171mm (96 x 96 DPI) 
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Tolerance to the evacuating solution.
1 = Very tolerable preparation. I would have no problem repeating it again.
2 = Preparation quite tolerable. I have had some discomfort, but I would not mind 
repeating it again.
3 = Moderately tolerable preparation. I have had discomfort but if it is necessary, 
I would repeat it again.
4 = Very annoying preparation. I have had a lot of discomfort. I would only repeat 
it if it is strictly necessary.
5 = Intolerable preparation. I would never repeat it again.
Tolerance to the diet.
1 = Diet very easy to follow. It has not interfered with my normal life. I have had 
no discomfort.
2 = Diet easy to follow. I have had to change my habits a little, but I have 
continued to lead a normal life. I have not noticed any discomfort.
3 = Moderately easy diet to follow. I have had to change my habits. Restrictive 
amounts. I've been a little hungry. I have not noticed any other discomfort.
4 = Diet very difficult to follow. I have had to change my habits. Very restrictive 
amounts. I've been very hungry. I also felt very tired and have lost weight
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5 = Diet almost impossible to follow. Very restrictive. I have been very hungry. I 
am very tired; I have insomnia and I have lost a lot of weight. I would never repeat 
it again.
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Additional table 2. PP segments cleansing and colonoscopy performance 






Cecal intubation time 
(m:s)
5:00 (4:00) 5:00 (3:00) ns
Time lapse between 
end preparation and 
colonoscopy  (h:m)
3:20 (0:56) 3:22 (0:53) ns
Withdrawal time (m:s) 13:00 (10:00) 14:00 (9:00) ns
Total colonoscopy time 
(m:s)
19:00 (12:00) 19:00 (11:00) ns
Cleansing
Proximal BBPS 0-1 4 (1.0%) 7 (1.7%) 0.031*
2 183 (44.0%) 205 (50.4%)
3 229 (55.0%) 195 (47.9%)
Transverse BBPS 0-1 3 (0.7%) 3 (0.7%) ns
2 129 (30.9%) 152 (37.3%)
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3 285 (68.3%) 252 (61.9%)
Distal BBPS 0-1 6 (1.4%) 8 (2.0%) ns
2 185 (44.4%) 181 (44.3%)
3 226 (54.2%) 220 (53.8%)
Global BBPS ≥ 8 Yes    254 (60.9%) 221 (54.0%) 0.046*
Performance
Adenoma detection Si 301 (72.2%) 299 (73.1%) ns
Polyp detection Si 325 (77.9%) 311 (76.0%) ns
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Age (years) 0.459 1.03 (0.95-1.1)
BMI (kg/m2) 0.582 0.97 (0.88-1.1)
Sex (Male) 0.818 1.10 (0.47-2.6)
Constipation 0.286 0.60 (0.23-1.55)
Antidepressant 0.148 0.45 (0.15-1.4)
1-Day LRD 0.502 1.47 (0.62-3.48)
Low diet tolerance 0.703 1.20 (0.46-3.1)
Low preparation tolerance 0.262 0.62 (0.26-1.45)
Days until colonoscopy 0.092 1.01 (0.99-1.02)
Page 38 of 41































































CONSORT 2010 checklist Page 1







1a Identification as a randomised trial in the title 1
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2
Introduction
2a Scientific background and explanation of rationale 4Background and 
objectives 2b Specific objectives or hypotheses 4, 5
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio 5Trial design
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
4a Eligibility criteria for participants 5Participants
4b Settings and locations where the data were collected 6
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered
6
6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed
7Outcomes
6b Any changes to trial outcomes after the trial commenced, with reasons
7a How sample size was determined 8Sample size
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
8a Method used to generate the random allocation sequence 5 Sequence 




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned
5,6
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions
5
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 6
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CONSORT 2010 checklist Page 2
assessing outcomes) and how
11b If relevant, description of the similarity of interventions
12a Statistical methods used to compare groups for primary and secondary outcomes 8Statistical methods
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome
9Participant flow (a 
diagram is strongly 
recommended) 13b For each group, losses and exclusions after randomisation, together with reasons 9
14a Dates defining the periods of recruitment and follow-up 5Recruitment
14b Why the trial ended or was stopped 5
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Done
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups
Done
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval)
9, 10Outcomes and 
estimation
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Done
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 12
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 12
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 13
Other information
Registration 23 Registration number and name of trial registry 5
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
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